Status:
COMPLETED
Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction
Lead Sponsor:
Yonsei University
Collaborating Sponsors:
ISU ABXIS (Korea pharmaceutical company)
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The ADMIRAL (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction) study demonstrated that early administration of abciximab in patients with ST elevation a...
Detailed Description
It is well known that platelet-mediated thrombosis is account for the pathophysiology of acute coronary syndrome (ACS) (1,2). In the treatment of ACS, intravenous platelet glycoprotein (GP) IIb/IIIa r...
Eligibility Criteria
Inclusion
- The patient must be at least 18-80 years of age.
- The patient had the symptoms of acute myocardial infarction within 12 hours with ST segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB.
- The patient or guardian agrees to the study protocol and provides informed, written consent.
Exclusion
- Patients to whom PCI can not be undergone within 12 hours from receiving the study drug
- Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg
- The history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding within recent 6 weeks;
- History of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
- Severe or malignant hypertension (= sitting SBP \> 180 mmHg and/or sitting DBP \> 105 mmHg)
- The patients who require oral anticoagulants during the trial; patients who have been administrated oral anticoagulants within 7 days
- The history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine is two times higher than the upper limit of normal of each center)
- The patients who could not take anti-platelet drugs
- The patients who might die of other disease than cardiac disease during the trial.
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
786 Patients enrolled
Trial Details
Trial ID
NCT00841438
Start Date
July 1 2007
End Date
December 1 2009
Last Update
May 4 2010
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Dankook University Hospital
Cheonan, South Korea, 330-716
2
Chonbuk National University Hospital
Cheonju, South Korea, 561-716
3
Keimyung University Dongsan Medical Center
Daegu, South Korea, 700-712
4
Kyungpook National University Hospital
Daegu, South Korea, 700-721